EGFR and cancer: In line with this result, selective inhibition of glucose metabolism using UK5099, a potent inhibitor of the mitochondrial pyruvate carrier, preferentially inhibited the growth of EGFR- and FGFR-dependent cancer cells (Supplementary Fig. 1m).